Trabectedin (Yondelis®). This drug binds to DNA
and interacts with DNA repair enzymes to disrupt the cell
cycle. It has demonstrated good clinical activity in Phase III
trials of patients with ovarian cancer.
21 enero 2007
New Cáncer Therapies for 2007 . Yondelis ( Trabectedin ) en pag. 4 .
Trabectedin (Yondelis®). This drug binds to DNA
and interacts with DNA repair enzymes to disrupt the cell
cycle. It has demonstrated good clinical activity in Phase III
trials of patients with ovarian cancer.